{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:33:53Z","timestamp":1792596833203,"version":"4.5.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK Alzheimer\u2019s Society","award":["AS-PG-16-006"],"award-info":[{"award-number":["AS-PG-16-006"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_17213"],"award-info":[{"award-number":["MC_PC_17213"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W014386\/1"],"award-info":[{"award-number":["MR\/W014386\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Cambridge Biomedical Research Unit in Dementia"},{"name":"Cambridgeshire and Peterborough NHS Foundation Trust"},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King\u2019s College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023232","name":"National Institute for Health Research Applied Research Collaboration South London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023232","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DATAMIND HDR UK Mental Health Data Hub","award":["MR\/W014386"],"award-info":[{"award-number":["MR\/W014386"]}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cambridge Centre for Parkinson\u2019s Plus disorders"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dementia with Lewy bodies (DLBs) is a common cause of dementia but has higher mortality than Alzheimer\u2019s disease (AD). The reasons for this are unclear, but antidementia drugs (including acetylcholinesterase inhibitors [AChEIs] and memantine) symptomatically benefit people with DLB and might improve outcomes. We investigated whether AChEIs and\/or memantine were associated with reduced hospital admissions and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study of those diagnosed with DLB between 1 January 2005 and 31 December 2019, using data from electronic clinical records of secondary care mental health services in Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), United Kingdom (catchment area population approximately 0.86 million), as well as linked records from national Hospital Episode Statistics (HES) data. Eligible patients were those who started AChEIs or memantine within 3 months of their diagnosis (cases) and those who never used AChEIs or memantine (controls). Outcomes included admission, length of stay, and mortality. Cox proportional hazard and linear regression models were used.<\/jats:p>\n                    <jats:p>\n                      Of 592 patients with DLB, 219 never took AChEIs or memantine, 100 took AChEIs only, and 273 took both AChEIs and memantine. The cohorts were followed up for an average of 896 days, 981 days, and 1,004 days, respectively. There were no significant differences in the cohorts\u2019 baseline characteristics, except for socioeconomic status that was lower in patients who never took AChEIs or memantine (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 23.34,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003). After controlling for confounding by sociodemographic factors (age, sex, marital status, ethnicity, socioeconomic status), antipsychotic use, antidepressant use, cognitive status, physical comorbidity, anticholinergic burden, and global health performance, compared with patients who never took AChEIs or memantine, patients taking AChEIs only or taking both had a significantly lower risk of death (adjusted hazard ratio (HR) = 0.67, 95% CI = 0.48 to 0.93,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02; adjusted HR = 0.64, 95% CI = 0.50 to 0.83,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001, respectively). Those taking AChEIs or both AChEIs and memantine had significantly shorter periods of unplanned hospital admission for physical disorders (adjusted coefficient \u221213.48, 95% CI = [\u221226.87, \u22120.09],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.049; adjusted coefficient \u221214.21, 95% CI = [\u221224.58, \u22123.85],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.007, respectively), but no difference in length of stay for planned admissions for physical disorders, or for admissions for mental health disorders. No significant additional associations of memantine on admission, length of stay, and mortality were found (all\n                      <jats:italic>P<\/jats:italic>\n                      &gt; 0.05). The main limitation was that this was a naturalistic study and possible confounds cannot be fully controlled, and there may be selection bias resulting from nonrandom prescription behaviour in clinical practice. However, we mimicked the intention-to-treat design of clinical trials, and the majority of baseline characters were balanced between cohorts. In addition, our series of sensitivity analyses confirmed the consistency of our results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, we observed that use of AChEIs with or without memantine in DLB was associated with shorter duration of hospital admissions and decreased risk of mortality. Although our study was naturalistic, it supports further the use of AChEIs in DLB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004124","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:08:12Z","timestamp":1670335692000},"page":"e1004124","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4724-4892","authenticated-orcid":true,"given":"Shanquan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5505-5231","authenticated-orcid":true,"given":"Annabel C.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-5167","authenticated-orcid":true,"given":"Rudolf N.","family":"Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2874-8307","authenticated-orcid":true,"given":"Sin\u00e9ad","family":"Moylett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne D.","family":"Kershenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-1686","authenticated-orcid":true,"given":"Christoph","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4435-6397","authenticated-orcid":true,"given":"Robert","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-5080","authenticated-orcid":true,"given":"John T.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"4","key":"pmed.1004124.ref001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0033291713000494","article-title":"The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies","volume":"44","author":"SA Vann Jones","year":"2014","journal-title":"Psychol Med"},{"issue":"5","key":"pmed.1004124.ref002","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","article-title":"The prognosis of dementia with Lewy bodies","volume":"16","author":"C Mueller","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"pmed.1004124.ref003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-018-0350-6","article-title":"Clinical prevalence of Lewy body dementia","volume":"10","author":"JPM Kane","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"pmed.1004124.ref004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.dadm.2017.12.001","article-title":"Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications","volume":"10","author":"C Mueller","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"issue":"7","key":"pmed.1004124.ref005","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jalz.2018.02.011","article-title":"Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia","volume":"14","author":"ECK Tan","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"17","key":"pmed.1004124.ref006","doi-asserted-by":"crossref","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","article-title":"Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality","volume":"96","author":"H Xu","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"pmed.1004124.ref007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/ageing\/afx098","article-title":"Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer\u2019s disease: a retrospective survival analysis","volume":"47","author":"C Mueller","year":"2018","journal-title":"Age Ageing"},{"issue":"33","key":"pmed.1004124.ref008","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer\u2019s disease","volume":"34","author":"P Nordstrom","year":"2013","journal-title":"Eur Heart J"},{"issue":"24","key":"pmed.1004124.ref009","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"M Emre","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"pmed.1004124.ref010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis","volume":"172","author":"C Stinton","year":"2015","journal-title":"Am J Psychiatry"},{"key":"pmed.1004124.ref011","doi-asserted-by":"crossref","first-page":"104474","DOI":"10.1016\/j.archger.2021.104474","article-title":"Treatment Efficacy and Acceptabilityof Pharmacotherapies for Dementia with Lewy Bodies: A Systematic Review and Network Meta-Analysis","volume":"96","author":"CS Chu","year":"2021","journal-title":"Arch Gerontol Geriatr"},{"issue":"3","key":"pmed.1004124.ref012","first-page":"1611","article-title":"Cholinesterase inhibitors and memantine for Parkinson\u2019s disease dementia and Lewy body dementia: A meta-analysis","volume":"17","author":"YH Meng","year":"2019","journal-title":"Exp Ther Med"},{"issue":"2","key":"pmed.1004124.ref013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"HF Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"pmed.1004124.ref014","doi-asserted-by":"crossref","first-page":"e017504","DOI":"10.1136\/bmjopen-2017-017504","article-title":"Mortality in dementia with Lewy bodies compared with Alzheimer\u2019s dementia: a retrospective naturalistic cohort study","volume":"7","author":"A Price","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"pmed.1004124.ref015","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/ije\/dyx015","article-title":"Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)","volume":"46","author":"A Herbert","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"1","key":"pmed.1004124.ref016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12911-017-0437-1","article-title":"Clinical records anonymisation and text extraction (CRATE): an open-source software system","volume":"17","author":"RN Cardinal","year":"2017","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"pmed.1004124.ref017","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"IG McKeith","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"pmed.1004124.ref018","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3233\/JAD-180877","article-title":"Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies","volume":"67","author":"S Moylett","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"pmed.1004124.ref019","unstructured":"Ministry of Housing CLG. English indices of deprivation 2015. 2015. https:\/\/www.gov.uk\/government\/statistics\/english-indices-of-deprivation-2015."},{"issue":"5","key":"pmed.1004124.ref020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"11","key":"pmed.1004124.ref021","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"H Quan","year":"2005","journal-title":"Med Care"},{"issue":"2\u20134","key":"pmed.1004124.ref022","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/00207459008986604","article-title":"Validation of the Mini-Mental State Examination","volume":"53","author":"AM Horton","year":"1990","journal-title":"Int J Neurosci"},{"issue":"4","key":"pmed.1004124.ref023","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"ZS Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"3\u20134","key":"pmed.1004124.ref024","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000351671","article-title":"Validation of the Addenbrooke\u2019s Cognitive Examination III in frontotemporal dementia and Alzheimer\u2019s disease","volume":"36","author":"S Hsieh","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"S1","key":"pmed.1004124.ref025","first-page":"S142","article-title":"The 2012 update to the anticholinergic cognitive burden scale","volume":"61","author":"NL Campbell","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"pmed.1004124.ref026","volume-title":"HoNOS: Health of the Nation Outcome Scales: Report on Research and Development July 1993-December 1995","author":"JK Wing","year":"1996"},{"key":"pmed.1004124.ref027","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2000"},{"issue":"19","key":"pmed.1004124.ref028","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"DF McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"pmed.1004124.ref029","unstructured":"STROBE. STROBE checklist for cohort studies. 2007. https:\/\/www.strobe-statement.org\/fileadmin\/Strobe\/uploads\/checklists\/STROBE_checklist_v4_cohort.pdf."},{"issue":"7","key":"pmed.1004124.ref030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00001756-199403000-00002","article-title":"Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer\u2019s disease","volume":"5","author":"EK Perry","year":"1994","journal-title":"Neuroreport"},{"issue":"11 Suppl 18","key":"pmed.1004124.ref031","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900014164","article-title":"The interplay of neurotransmitters in Alzheimer\u2019s disease","volume":"10","author":"PT Francis","year":"2005","journal-title":"CNS Spectr"},{"issue":"2","key":"pmed.1004124.ref032","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0269881116680924","article-title":"Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology","volume":"31","author":"JT O\u2019Brien","year":"2017","journal-title":"J Psychopharmacol"},{"key":"pmed.1004124.ref033","unstructured":"National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease. 2011. https:\/\/www.nice.org.uk\/guidance\/ta217\/resources\/donepezil-galantamine-rivastigmine-and-memantine-for-the-treatment-of-alzheimers-disease-pdf-82600254699973."},{"issue":"2","key":"pmed.1004124.ref034","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv086","article-title":"Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis","volume":"19","author":"S Matsunaga","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"pmed.1004124.ref035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jgs.15608","article-title":"Cause of Death and End-of-Life Experiences in Individuals with Dementia with Lewy Bodies","volume":"67","author":"MJ Armstrong","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"pmed.1004124.ref036","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.parkreldis.2019.03.014","article-title":"Causes and outcomes of hospitalization in Lewy body dementia: A retrospective cohort study","volume":"64","author":"CC Spears","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"pmed.1004124.ref037","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cardfail.2009.05.008","article-title":"Anti-Alzheimer\u2019s drug, donepezil, markedly improves long-term survival after chronic heart failure in mice","volume":"15","author":"T Handa","year":"2009","journal-title":"J Card Fail"},{"key":"pmed.1004124.ref038","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jneuroim.2003.11.003","article-title":"Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines","volume":"148","author":"M Reale","year":"2004","journal-title":"J Neuroimmunol"},{"key":"pmed.1004124.ref039","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jns.2004.11.030","article-title":"Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients","volume":"229\u2013230","author":"B Borroni","year":"2005","journal-title":"J Neurol Sci"},{"issue":"9","key":"pmed.1004124.ref040","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/jgs.15415","article-title":"Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta-Analysis and Systematic Review","volume":"66","author":"AT Isik","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"pmed.1004124.ref041","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/gps.4015","article-title":"Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer\u2019s dementia","volume":"29","author":"A Rongve","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"pmed.1004124.ref042","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000334523","article-title":"Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson\u2019s disease dementia","volume":"32","author":"V Larsson","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"pmed.1004124.ref043","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1185\/03007995.2011.582484","article-title":"Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer\u2019s disease: a multicenter, randomized, open-label, parallel-group study","volume":"27","author":"SH Choi","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"pmed.1004124.ref044","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1368-5031.2006.00967.x","article-title":"Cardiac safety of rivastigmine in Lewy body and Parkinson\u2019s disease dementias","volume":"60","author":"C Ballard","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"2","key":"pmed.1004124.ref045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/WAD.0b013e3181b7642b","article-title":"Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB)","volume":"24","author":"MH Rosenbloom","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"pmed.1004124.ref046","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","article-title":"Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies","volume":"88","author":"AW Lemstra","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"pmed.1004124.ref047","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","article-title":"Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both","volume":"64","author":"ML Kraybill","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"pmed.1004124.ref048","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias","volume":"25","author":"DR Howlett","year":"2015","journal-title":"Brain Pathol"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:08:54Z","timestamp":1670335734000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004124"}},"subtitle":[],"editor":[{"given":"Raquel C.","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004124","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}